The approval gives Korea a locally developed rival to Wegovy and Mounjaro, though reports note modest weight loss with fewer side effects and open pricing quest

The industry lobby argues the most-favored-nation style demonstration for Medicare Part B drugs is unlawful, escalating a legal fight over US drug pricing.

The decision trims Pfizer's late-stage obesity pipeline at a time when it is counting on metabolic drugs to offset falling COVID revenue.

The NPPA proposal would sharply cut retail prices on oncology medicines, a major affordability move in one of the world's largest generics markets.

Rhapsido becomes the first approved treatment for chronic friction hives, expanding Novartis's immunology franchise.

Investors focused on glycemic results from petrelintide, keeping Jefferies at hold and highlighting a crowded next-generation obesity field.

The stock reversed a double-digit after-hours jump as investors judged the domestic approval already priced in, even as iM Securities raised its target on the o

The nod extends immunotherapy into earlier, curative-intent colon cancer, expanding the addressable population for Roche's Tecentriq.

The appeal moves one of the industry's key constitutional challenges to the IRA drug price negotiation regime to a federal appellate court.

Lilly is using acquisitions and adjacent indications to defend its position at the top of the obesity market.

An analyst raised approval odds for Replimune's melanoma therapy after what was described as an overwhelmingly positive advisory panel.

The regimen adds a maintenance option for HER2-positive metastatic breast cancer, deepening the targeted-therapy stack in that setting.

The review questions how much patients actually save under the administration's direct-to-consumer drug pricing platform.

Regulatory and pricing moves could broaden access to lower-cost versions of popular weight loss medicines.

The filing targets a broader chronic kidney disease population beyond diabetic patients, a large and underserved group.

Companies are reworking commercial strategies to reach patients directly as obesity drugs become consumer products.

The next generation of obesity treatments is advancing toward market, intensifying competition across the GLP-1 class.

The coming date is tied to pricing changes that could raise costs for a large group of prescription drug users.